Cited by

• Novel Mutations in AKT1 Gene in Prostate Cancer Patients in Jordan.

  Alasmar A, Al-Alami Z, Zein S, Al-Smadi A, Al Bashir S, Alorjani MS, Al-Zoubi RM, Al Zoubi M. Alasmar A, et al. Curr Issues Mol Biol. 2024 Sep 4;46(9):9856-9866. doi: 10.3390/cimb46090586. Curr Issues Mol Biol. 2024. PMID: 39329938 Free PMC article.
• Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis.

  Chen Y, Huang L, Dong Y, Tao C, Zhang R, Shao H, Shen H. Chen Y, et al. Front Cell Dev Biol. 2020 Oct 6;8:573599. doi: 10.3389/fcell.2020.573599. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33123537 Free PMC article.
• Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

  Meijer TWH, Looijen-Salamon MG, Lok J, van den Heuvel M, Tops B, Kaanders JHAM, Span PN, Bussink J. Meijer TWH, et al. Thorac Cancer. 2019 Dec;10(12):2289-2299. doi: 10.1111/1759-7714.13226. Epub 2019 Oct 30. Thorac Cancer. 2019. PMID: 31668020 Free PMC article.
• AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer.

  Malanga D, Belmonte S, Colelli F, Scarfò M, De Marco C, Oliveira DM, Mirante T, Camastra C, Gagliardi M, Rizzuto A, Mignogna C, Paciello O, Papparella S, Fagman H, Viglietto G. Malanga D, et al. PLoS One. 2016 Feb 9;11(2):e0147334. doi: 10.1371/journal.pone.0147334. eCollection 2016. PLoS One. 2016. PMID: 26859676 Free PMC article.
• Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

  Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B. Yu Y, et al. PLoS One. 2015 Oct 15;10(10):e0140479. doi: 10.1371/journal.pone.0140479. eCollection 2015. PLoS One. 2015. PMID: 26469692 Free PMC article.